A Phase 3 interventional study of tadalafil and Placebo in Impotence, sponsored by Eli Lilly and Company. Completed at 19 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-10.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 20th largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2006, is one of 19 in phase 3, and was the 9th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 342 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 18th largest by enrollment, is the only one that started in 2006, is one of 13 in phase 3, and was the 5th registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine if tadalafil 5 mg daily compared to placebo when given for 12 weeks improves getting and maintaining an erection in men with erectile dysfunction and if there are improvements in the sexual quality of life of the man and his female study partner
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male
Exclusion Criteria:
Placebo
Drug: Placebo
5 mg tadalafil
Drug: tadalafil
5 mg tadalafil tablet taken by mouth once a day for 12 weeks
Also known as: LY450190, Cialis, IC351
placebo tablet taken by mouth once a day for 12 weeks
Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15)
Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.
Time frame: Baseline and 12 weeks
Improvement in the Sexual Quality of Life in the Subject and His Study Partner as Measured by the Sexual Quality of Life (SQoL) Domain of the Sexual Life Quality Questionnaire (SLQQ)
The original item scores (-4 to 4 range) were converted to 0 to 8 scale score by adding 4 to each recorded responses. Each transformed score was multiplied by 12.5 for a total range of 0 to 100. Higher scores are indicative of a higher sexual quality of life.
Time frame: Baseline and 12 weeks
Change From Baseline to Endpoint in the Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Diary Questions 2 (SEP2) and 3 (SEP3).
The baseline and endpoint score for each SEP question 2 (Insert penis into vagina) and 3 (Successful intercourse) are the subject's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.
Time frame: Baseline and 12 weeks
Change From Baseline to Week 12 Endpoint in the International Index of Erectile Function - Intercourse Satisfaction Domain - Subject Response
Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Overall Satisfaction Domain of the International Index of Erectile Function (IIEF-OS) - Subject Response
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.
Time frame: Baseline and 12 weeks
Sexual Life Quality Questionnaire (SLQQ) Treatment Satisfaction Domain
The 6 SLQQ-treatment satisfaction questions were answered by subject and partner at Visit 4/Final Visit. Original item scores (1 to 6 range) were converted to 0 to 5 scale by subtracting 1 to each recorded responses. Each transformed score was multiplied by 20. Total range of scores: 0 (low satisfaction) to 100 (high satisfaction).
Time frame: 12 weeks
Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 4 and 5 - Subject Response
The baseline and endpoint score for each SEP question 4 (Satisfied with hardness) and 5 (Satisfied overall) are the subject's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Question 3 - Partner Response
The baseline and endpoint score for partner SEP question 3 (Satisfied overall) are the partner's percentage of "yes" responses to the question during the run-in period and postbaseline period, respectively.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in the Satisfaction Domain of the Female Sexual Function Index (FSFI) - Partner Response
The FSFI Satisfaction Domain (items 14-16) measures satisfaction with emotional closeness, sexual relationship, and overall sexual life. Each question is scored on a 0/1 to 5 scale and domain score is calculated by multiplying the total points by 0.4, for a total score range of 0.8 to 6, with higher scores indicating greater satisfaction.
Time frame: Baseline and 12 weeks
Percent of Subjects With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Subject Response
Percent of subjects with "Yes" responses to Question 1 (Improvement in Erections) and Question 2 (Improvement in the Ability to Engage in Sexual Activity)
Time frame: 12 weeks
Percent of Partners With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Partner Response
Percent of Partners with "Yes" responses to Question 1 (Improvement in Erections) and Question 2 (Improvement in the Ability to Engage in Sexual Activity)
Time frame: 12 weeks
Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Questions 1 and 2 - Partner Response
The baseline and endpoint score for each SEP question 1 (Achieve some erection) and 2 (Insert penis into vagina) are the partner's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire
Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire - Confidence Domain Subscales
Measures improvement in confidence (items 9-14). Confidence domain consists of two subscales (Self-Esteem, items 9-12; Overall Relationship, items 13 and 14). Each domain score, subscale score, and overall score are transformed onto a 0 (least favorable) to 100 (most favorable) scale.
Time frame: Baseline and 12 weeks
| Milestone | Placebo | Tadalafil |
|---|---|---|
| Started | 78 | 264 |
| Completed | 64 | 243 |
| Not completed | 14 | 21 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Protocol violation | 1 | 6 |
| Withdrew: Withdrawal by subject | 12 | 8 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Partner decision | 0 | 3 |
Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15) | 0.49 ± 0.781 | 8.03 ± 0.449 |
The original item scores (-4 to 4 range) were converted to 0 to 8 scale score by adding 4 to each recorded responses. Each transformed score was multiplied by 12.5 for a total range of 0 to 100. Higher scores are indicative of a higher sexual quality of life.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| SQoL - Subject (change from baseline) | 12.59 ± 2.866 | 39.37 ± 1.651 |
| SQoL-Partner (change from baseline) (n=70, n=238) | 7.93 ± 2.861 | 32.87 ± 1.638 |
Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Change From Baseline to Week 12 Endpoint in the International Index of Erectile Function - Intercourse Satisfaction Domain - Subject Response | 0.09 ± 0.356 | 2.74 ± 0.205 |
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Change From Baseline to 12 Week Endpoint in Overall Satisfaction Domain of the International Index of Erectile Function (IIEF-OS) - Subject Response | 0.44 ± 0.257 | 2.57 ± 0.148 |
The 6 SLQQ-treatment satisfaction questions were answered by subject and partner at Visit 4/Final Visit. Original item scores (1 to 6 range) were converted to 0 to 5 scale by subtracting 1 to each recorded responses. Each transformed score was multiplied by 20. Total range of scores: 0 (low satisfaction) to 100 (high satisfaction).
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| SLQQ - Subject (n=72, n=244) | 51.58 ± 2.246 | 75.04 ± 1.293 |
| SLQQ - Partner (n=70, n=238) | 55.25 ± 2.115 | 73.42 ± 1.214 |
The baseline and endpoint score for each SEP question 2 (Insert penis into vagina) and 3 (Successful intercourse) are the subject's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.
| percent | Placebo | Tadalafil |
|---|---|---|
| Question 2 change from baseline in percent "yes" | 2.19 ± 2.833 | 28.80 ± 1.644 |
| Question 3 change from baseline in percent "yes" | 10.80 ± 3.767 | 46.46 ± 2.185 |
The baseline and endpoint score for each SEP question 4 (Satisfied with hardness) and 5 (Satisfied overall) are the subject's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.
| percent | Placebo | Tadalafil |
|---|---|---|
| Question 4 change from baseline in percent "Yes" | 12.08 ± 3.936 | 50.05 ± 2.283 |
| Question 5 change from baseline in percent "Yes" | 11.47 ± 3.951 | 48.78 ± 2.292 |
The baseline and endpoint score for partner SEP question 3 (Satisfied overall) are the partner's percentage of "yes" responses to the question during the run-in period and postbaseline period, respectively.
| percent | Placebo | Tadalafil |
|---|---|---|
| Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Question 3 - Partner Response | 10.21 ± 3.595 | 43.16 ± 2.072 |
The FSFI Satisfaction Domain (items 14-16) measures satisfaction with emotional closeness, sexual relationship, and overall sexual life. Each question is scored on a 0/1 to 5 scale and domain score is calculated by multiplying the total points by 0.4, for a total score range of 0.8 to 6, with higher scores indicating greater satisfaction.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Change From Baseline to 12 Week Endpoint in the Satisfaction Domain of the Female Sexual Function Index (FSFI) - Partner Response | -0.40 ± 0.130 | 0.32 ± 0.075 |
Percent of subjects with "Yes" responses to Question 1 (Improvement in Erections) and Question 2 (Improvement in the Ability to Engage in Sexual Activity)
| percentage of subjects answering Yes | Placebo | Tadalafil |
|---|---|---|
| GAQ Question 1 | 26 | 81 |
| GAQ Question 2 | 22 | 79 |
Percent of Partners with "Yes" responses to Question 1 (Improvement in Erections) and Question 2 (Improvement in the Ability to Engage in Sexual Activity)
| percentage of partners answering Yes | Placebo | Tadalafil |
|---|---|---|
| GAQ Question 1 | 30 | 79 |
| GAQ Question 2 | 24 | 76 |
The baseline and endpoint score for each SEP question 1 (Achieve some erection) and 2 (Insert penis into vagina) are the partner's percentage of "yes" responses to those questions during the run-in period and postbaseline period, respectively.
| percent | Placebo | Tadalafil |
|---|---|---|
| Question 1 change from baseline in percent "Yes" | 1.25 ± 2.224 | 18.34 ± 1.270 |
| Question 2 change from baseline in percent "Yes" | 6.97 ± 2.896 | 30.69 ± 1.662 |
Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Total Score change from baseline | 3.07 ± 2.616 | 30.44 ± 1.506 |
| Sexual Relationship change from baseline | 4.61 ± 2.903 | 34.28 ± 1.673 |
| Confidence change from baseline | 0.91 ± 2.567 | 25.35 ± 1.475 |
Measures improvement in confidence (items 9-14). Confidence domain consists of two subscales (Self-Esteem, items 9-12; Overall Relationship, items 13 and 14). Each domain score, subscale score, and overall score are transformed onto a 0 (least favorable) to 100 (most favorable) scale.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Self-Esteem change from baseline | 3.26 ± 2.743 | 29.56 ± 1.579 |
| Overall Relationship change from baseline | -4.04 ± 2.792 | 16.97 ± 1.603 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | — | — |
| Tadalafil | — | — | — |
| Event | Placebo | Tadalafil |
|---|---|---|
| PancreatitisGastrointestinal disorders | 1/78 | 0/264 |
| HypersensitivityImmune system disorders | 0/78 | 1/264 |
| GastroenteritisInfections and infestations | 0/78 | 1/264 |
| Cerebrovascular accidentNervous system disorders | 0/78 | 1/264 |
| Event | Placebo | Tadalafil |
|---|---|---|
| HeadacheNervous system disorders | 3/78 | 22/264 |
| DyspepsiaGastrointestinal disorders | 0/78 | 12/264 |
| GastroenteritisInfections and infestations | 3/78 | 2/264 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/78 | 7/264 |
| FatigueGeneral disorders | 2/78 | 0/264 |
| DiarrhoeaGastrointestinal disorders | 1/78 | 5/264 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/78 | 5/264 |
| Back painMusculoskeletal and connective tissue disorders | 1/78 | 5/264 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/78 | 5/264 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/78 | 4/264 |
| Age Continuous(years) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mean | 53.82 ± 10.72 | 54.42 ± 10.04 | 54.29 ± 10.18 |
| Sex: Female, Male(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 78 | 264 | 342 |
| Region of Enrollment(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| France | 11 | 41 | 52 |
| United States | 29 | 107 | 136 |
| Mexico | 19 | 63 | 82 |
| Austria | 8 | 17 | 25 |
| Germany | 11 | 36 | 47 |
| Erectile Dysfunction History - Duration(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| >= 1 year | 73 | 240 | 313 |
| >= 3 months and < 6 months | 1 | 8 | 9 |
| >= 6 months and < 1 year | 4 | 16 | 20 |
| Erectile Dysfunction History - Etiology(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mixed | 34 | 114 | 148 |
| Organic | 29 | 91 | 120 |
| Psychogenic | 12 | 30 | 42 |
| Unknown | 3 | 29 | 32 |
| International Index of Erectile Function (IIEF) - Erectile Dysfunction Severity(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mild (17-30) | 35 | 123 | 158.0 |
| Moderate (11-16) | 22 | 71 | 93.0 |
| Severe (1-10) | 20 | 63 | 83.0 |
| Missing | 1 | 7 | 8.0 |
| Race/Ethnicity(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| African | 0 | 6 | 6 |
| Caucasian | 57 | 188 | 245 |
| Hispanic | 21 | 69 | 90 |
| Native American | 0 | 1 | 1 |
| International Index of Erectile Function (IIEF) - Erectile Function Domain(units on a scale) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mean | 15.27 ± 6.49 | 15.73 ± 6.13 | 15.62 ± 6.21 |
The record gives a start of Nov 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil